Home › Cancer types › Prostate Cancer

Just diagnosed with prostate cancer?

By the Cancer Clues team · Last updated 1 November 2026 · How we grade treatments

The honest numbers

One number first, because statistics describe groups, never one person — your own outlook depends on your risk group, which your team can explain in minutes.

• About 334,000 US diagnoses expected in 2026; roughly 1 man in 8 is diagnosed in his lifetime; median age 68 [1].
• Five-year relative survival: 98% overall; effectively 100% for cancer still in or near the prostate (that's 7–8 of every 10 diagnoses); 40% once distant spread has occurred (about 1 in 11 diagnoses) [1].
• The landmark ProtecT trial followed 1,643 men with screen-detected localized cancer for 15 years: death from prostate cancer was around 3% whichever path they took — monitoring, surgery, or radiation [2].

What's actually proven

For localized disease there are three main paths, and the honest headline from the best trial ever run (ProtecT, 15 years) is that survival was the same on all three [2]:

• Active surveillance — regular PSA tests, scans and biopsies, treating only if the cancer shows signs of progressing. For low-risk disease this is a standard, guideline-backed choice, not “doing nothing” [3][4].
• Surgery (radical prostatectomy) and radiation (with or without a period of hormone therapy) — equivalent survival; they differ in side-effect profiles (urinary and sexual effects for surgery; bowel and urinary irritation for radiation) [2][4].
• One nuance worth knowing: immediate treatment roughly halved the risk of metastases in ProtecT without changing 15-year survival — a real consideration for younger men and higher-risk disease [2].
• For advanced disease: hormone therapy is the backbone, now usually intensified with newer androgen-receptor drugs, sometimes chemotherapy [4].

Depth, stage by stage, from the sources doctors use: the National Cancer Institute's patient guide [3] and the NCCN patient guidelines (early and advanced) [4].

What people ask about (from our graded library)

• High-dose IV vitamin C — graded Promising overall, but the honest prostate-specific note: the one randomized, placebo-controlled trial in prostate cancer (47 men, with chemotherapy) found no benefit at all [5].
• Fenbendazole — heavily discussed in prostate forums; no human trial exists, and the published severe liver-injury case was a prostate-cancer patient self-dosing fenbendazole plus ivermectin for three months [6].
• Supplements marketed “for prostate health” (saw palmetto, lycopene and friends) — none has credible evidence against cancer; our wording rule applies to everyone, including us: anything sold as treating cancer is being sold illegally.
• Browse the full graded library — and tell your team about anything you take; several supplements interact with hormone therapy or surgery (bleeding).

Does the hospital matter?

For prostate surgery specifically: yes, the surgeon's experience measurably matters. A study of 7,765 patients found the risk of cancer recurrence falls steeply with the surgeon's career case count, levelling off only after roughly 250 operations [7]. The question to ask is polite and fair: “How many of these do you do a year, and how many have you done?” Radiation quality is more standardized, and surveillance programs matter most for consistency of follow-up. Choosing an experienced high-volume team — which need not be the most famous name — is the highest-value “where” decision here. Our hospital guide explains how to check, and we can organize a second opinion.

What's new (and real)

• PSMA-PET scans — a far more sensitive way to see where prostate cancer is; now guideline-preferred for investigating rising PSA after treatment, where it changes the plan in roughly half of cases [8].
• Pluvicto (lutetium-177 PSMA) — a radioactive drug that homes in on prostate-cancer cells; in March 2025 the FDA approved it for use before chemotherapy in PSMA-positive resistant metastatic disease, roughly tripling who's eligible [9].
• Genomic test scores (Decipher and similar) increasingly help decide how intensive surveillance or treatment should be [4].

Questions for your oncologist (bring this list)

1. What is my risk group (PSA, grade, stage) — and is active surveillance a safe option for me?
2. If treatment: what are my odds of urinary, sexual and bowel side effects, with your team specifically?
3. For surgery: how many prostatectomies has the surgeon done?
4. Would a PSMA-PET scan change my staging or plan?
5. Is there a clinical trial that fits my situation?

Common questions